New antihemorrhagic agents: a novel antifibrinolytic strategy

-
Hemorrhage is a leading cause of death and cost associated with blood transfusion.
-
There is a need for the improvement of current treatments of bleeding associated with surgery, trauma, intracerebral hemorrhage (ICH) or other tissue damages.
-
A novel target involved in fibrinolysis has been identified.
-
Proprietary novel compounds to prevent major bleeding have been developed:
-
Small molecule entity (SME).
-
Efficacy: 30,000 times more effective than the currently available therapies.
-
Safety: No thrombus formation and no impact on coagulation.
-
-
Primary Indication: prophylaxis and acute treatment of bleeding in cardiac surgery.
![]() |
Research Programs Research programs in which you can participate with CIMA CIMA Research Programs and Agreements [PDF] |

Its objective is to optimize the range of genetic and immunophenotypic diagnoses carried out in different laboratories of the University of Navarra with the highest level of quality and innovation. |
Contact us: |
Contact:
Center for Applied Medical Research (CIMA) Avenida Pío XII, 55 31008 Pamplona Spain +34 948 194700 cima@unav.es |